Improving biochemical markers for disorders of N-glycosylation

Affiliations

Editorial

Hudson H Freeze. Ann Transl Med. 2019 Sep.

. 2019 Sep;7(Suppl 6):S176.

doi: 10.21037/atm.2019.07.79.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Increased Clinical Sensitivity and Specificity of Plasma Protein N-Glycan Profiling for Diagnosing Congenital Disorders of Glycosylation by Use of Flow Injection-Electrospray Ionization-Quadrupole Time-of-Flight Mass Spectrometry.
Chen J, Li X, Edmondson A, Meyers GD, Izumi K, Ackermann AM, Morava E, Ficicioglu C, Bennett MJ, He M. Chen J, et al. Clin Chem. 2019 May;65(5):653-663. doi: 10.1373/clinchem.2018.296780. Epub 2019 Feb 15. Clin Chem. 2019. PMID: 30770376 Free PMC article.

1. Chen J, Li X, Edmondson A, et al. Increased clinical sensitivity and specificity of plasma protein N-glycan profiling for diagnosing congenital disorders of glycosylation by use of flow injection-electrospray ionization-quadrupole time-of-flight mass spectrometry. Clin Chem 2019;65:653-63. 10.1373/clinchem.2018.296780 - DOI - PMC - PubMed
1. Ng BG, Freeze HH. Perspectives on Glycosylation and Its Congenital Disorders. Trends Genet 2018;34:466-76. 10.1016/j.tig.2018.03.002 - DOI - PMC - PubMed
1. Chang IJ, He M, Lam CT. Congenital disorders of glycosylation. Ann Transl Med 2018;6:477. 10.21037/atm.2018.10.45 - DOI - PMC - PubMed
1. O'Flaherty R, Trbojević-Akmačić I, Greville G, et al. The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins. Expert Rev Proteomics 2018;15:13-29. 10.1080/14789450.2018.1404907 - DOI - PubMed
1. Keser T, Pavić T, Lauc G, et al. Comparison of 2-aminobenzamide, procainamide and RapiFluor-MS as derivatizing agents for high-throughput HILIC-UPLC-FLR-MS N-glycan analysis. Front Chem 2018;6:324. 10.3389/fchem.2018.00324 - DOI - PMC - PubMed